FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

63 letters match. Newest first.

  1. Umicore Argentina S.A.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  2. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  3. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  4. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  5. Curia New York, Inc.

    FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.

    High risk
  6. Kellin Chemicals Co., Ltd. - Zhangjiagang

    Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.

    High risk
  7. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  8. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  9. Almon Healthcare Private Limited

    Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.

    High risk
  10. Shimoga Chemicals

    FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.

    High risk
  11. Fareva Amboise

    FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.

    High risk
  12. International Medication Systems Limited

    FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.

    High risk
  13. Pharmathen International S.A.

    FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.

    High risk
  14. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  15. Alchymars ICM SM Private Limited

    FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.

    High risk
  16. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  17. Hangzhou Yiqi Biotechnology Co., Ltd

    FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

    High risk
  18. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  19. Henan Lvyuan Pharmaceutical Co. Ltd.

    FDA warns Henan Lvyuan Pharmaceutical over CGMP failures at its API plant, including water leaks and incomplete batch records.

    High risk
  20. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk
  21. A. Nelson & Co. Ltd.

    London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.

    High risk
  22. Chemspec Chemicals Private Limited

    FDA warns Indian API maker Chemspec Chemicals over missing batch records and data integrity failures.

    High risk
  23. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  24. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  25. Seema International

    FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.

    High risk
  26. Scientific Protein Laboratories, LLC

    FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

    High risk
  27. Chengdu Brilliant Biopharmaceutical Co., Ltd.

    FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.

    High risk
  28. Hikal Limited

    FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.

    High risk
  29. Macsen Drugs

    FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.

    High risk
  30. Mentha & Allied Products Private Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  31. Aspen Biopharma Labs Private Limited

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  32. Shree Jaya Laboratories PVT. LTD.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  33. Tyche Industries Ltd

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  34. Chengdu Innovation Pharmaceutical Co., Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  35. Wuhu Nuowei Chemistry Co., Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  36. Center for Instrumental Analysis of China Pharmaceutical University

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  37. Global Calcium Pvt. Limited

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  38. Sanofi

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  39. Micro Orgo Chem

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  40. Antaria Pty. Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  41. Sichuan Deebio Pharmaceutical Co. Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  42. Mei Lan Thailand Co., Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Refused Inspection

  43. ALI Pharmaceutical Manufacturing, LLC

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  44. Sun Pharmaceutical Industries Ltd.

    FDA warns Sun Pharmaceutical over CGMP violations in sterile injectable manufacturing at its Halol, India facility.

    High risk
  45. Centaur Pharmaceuticals Private Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  46. Chengdu KeCheng Fine Chemicals Co., Ltd.

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  47. MD Pharmaceutical Supply, LLC

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  48. Nortec Quimica SA

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  49. Centrient Pharmaceuticals India Private Limited

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

  50. Lupin Limited

    CGMP/Active Pharmaceutical Ingredient (API)/Adulterated